 |
|
EDUCATION
1997 : Degree in Medicine, School of Medicine, Moscow State Medical Stomatology University
2011: PhD in Hematology, School of Medicine, University of Crete, Greece
PROFESSIONAL EXPERIENCE
1998-2001: Medical Doctor in rural service
2001-2003: Residency in Internal Medicine, Venizeleio General Hospital of Heraklion, Crete, Greece
2003-2004: Locum Residency 4th Blood Center, Venizeleio General Hospital of Heraklion, Crete, Greece
2004-2008: Hematology Residency, Hematology Department, University Hospital of Heraklion, Crete,Greece
2008-2009: Consultant physician, Department of Blood Transfusion, University Hospital of Heraklion, Crete, Greece
2009-2010: Consultant physician, Department of Blood Transfusion, Venizeleio General Hospital of Heraklion, Crete, Greece
2011- : Consultant physician, Department of Hematology, Venizeleio General Hospital of Heraklion, Crete, Greece
RESEARCH INTERESTS
Immune Thrombocytopenia patient registry
SELECTED PEER-REVIEWED PUBLICATIONS
1. Stavroulaki E, Kastrinaki MC, Pontikoglou C, Eliopoulos D, Damianaki A, Mavroudi I, Pyrovolaki K, Katonis P, Papadaki HA. Mesenchymal stem cells contribute to the abnormal bone marrow microenvironment in patients with chronic idiopathic neutropenia by overproduction of transforming growth factor-β1.Stem Cells Dev. 2011 Aug;20(8):1309-18. doi: 10.1089/scd.2010.0425. Epub 2010 Dec 27.
2. Kastrinaki MC, Pontikoglou C, Klaus M, Stavroulaki E, Pavlaki K, Papadaki HA.
.Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.Curr Stem Cell Res Ther. 2011 Jun;6(2):122-30. Review
3. Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, Psyallaki M, Pontikoglou CG, Tsoukatou D, Mamalaki C, Papadaki HA. Reserves, functional, immunoregulatory and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2009 Sep 29.
4. Eliopoulos DG, Mavroudi I, Pontikoglou C, Ximeri M, Stavroulaki E, Pyrovolaki K, Velegraki M, Spanoudakis M, Goulielmos G, Papadaki HA.The -509C/T polymorphism of transforming growth factor-beta1 is associated with increased risk for development of chronic idiopathic neutropenia. Eur J Haematol. 2009 Jul 14
5.Papadaki HA, Damianaki A, Pontikoglou C, Pyrovolaki K, Eliopoulos DG, Stavroulaki E, Eliopoulos GD.Increased levels of soluble flt-3 ligand in serum and long-term bone marrow culture supernatants in patients with chronic idiopathic neutropenia.Br J Haematol. 2006 Mar;132(5):637-9.
6. Papadaki HA, Pontikoglou C, Stavroulaki E, Eliopoulos DG, Mavroudi I, Spanoudakis M, Eliopoulos GD Soluble c-kit ligand production by bone marrow stromal cells is independent of the degree of neutropenia in patients with chronic idiopathic neutropenia. Ann Hematol. 2006 Mar;85(3):170-3. Epub 2006 Jan 4.
7. Papadaki HA, Pontikoglou C, Stavroulaki E, Minadakis G, Eliopoulos DA, Pyrovolaki K, Skordilis P, Eliopoulos GD High prevalence of Helicobacter pylori infection and monoclonal gammopathy of undetermined significance in patients with chronic idiopathic neutropenia.
Ann Hematol. 2005 May;84(5):317-20. Epub 2005 Feb 25.
